Mirum Pharmaceuticals initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Mirum Pharmaceuticals (MIRM) with an Outperform rating and $130 price target The firm’s checks suggest Livmarli, along with the bile acid portfolio, should generate sustained revenue growth “well into the next decade,” says the analyst, adding that the firm’s analysis suggests volixibat’s PSC readout is “more likely to succeed than not,” making it the “next major catalyst.”